Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- Wearable technologies may transform patient care, clinical research
-
- Analysis of the Canadian hypertension guidelines and the impact on upcoming recommendations Roger S. Blumenthal, MD; J. William McEvoy, MB BCh, BAO, MRCP; Seamus P. Whelton, MD, MPH; Haitham M. Ahmed, MD, MPH
- FDA: ROCKET AF results not affected by faulty INR monitoring device
- Medtronic implantable devices approved by FDA for use in 3-T MRI systems
- Antisense oligonucleotide associated with substantial reductions in Lp(a) concentrations
- Biodegradable polymer SES noninferior to BES for target lesion failure at 1 year
- Calcium supplementation may raise risk for CAC
- Changes in fat quality, quantity linked to intensified CVD risk factors
- Gene affecting platelet activity tied to pathogenesis of CVD
-
- INR stability inconsistent among patients with AF assigned warfarin
- Intracoronary abciximab may improve primary PCI in patients with diabetes, STEMI
- In-transit telemedicine reduces time to treatment for ischemic stroke
- Obesity may be independently associated with incident HF, but not CHD or stroke
- Regular moderate-vigorous physical activity may lower health care costs
- Sex hormones fail to influence all-cause, CVD mortality in middle-aged men
- Statins, nonstatin LDL-lowering therapies associated with similar CV benefit
- Stroke risk increases with low-normal TSH levels
-
- Therapeutic hypothermia fails to benefit patients with in-hospital cardiac arrest
- Sexual difficulties common after acute MI, especially in women
- Cardiologist to lead presidential advisory committee on global health
- HHS finalizes MACRA payment system for physicians
- Trial of high-dose influenza vaccine in patients with HF, MI launches
- DISRUPT PAD: Lithoplasty system successfully treats calcified lesions in patients with PAD
- A look at new therapeutic advances for HF management
- ANNEXA-4: Reversal agent effective in patients with acute major bleeding after Factor Xa inhibitor use
-
- Be accurate, thorough when coding patient visits
- Change in cardiorespiratory fitness over time linked with CV event risk
- DANISH: Prophylactic ICD implantation not superior to usual care in some patients with systolic HF
- ESPRIT I: BVS for PAD safe, linked to low event rate at 3 years
- Experts, patients come together to address barriers to PCSK9 inhibitor access
- Familial chylomicronemia syndrome associated with ‘considerable’ clinical, psychosocial burden
- LAPTOP-HF: Left atrial pressure-guided therapy may benefit patients with HF
- MOBILE: Cell therapy may improve outcomes in patients with CLI
-
- OPTICARE: Enhanced cardiac rehabilitation program improves quality of life, but not CV risk score
- Sacubitril/valsartan associated with better quality-of-life metrics vs. enalapril
- Salt taste sensitivity declines with dietary changes in patients with acute decompensated HF
- SWAP-HF: Palliative care initiative may improve quality of care for patients with advanced HF
- TACTICS-HF: Tolvaptan fails to improve congestion, worsens renal function in patients with acute HF
- Trial Scorecard: CALIBER
- Trial Scorecard: DANISH
- Trial Scorecard: DISRUPT PAD
-
- Trial Scorecard: ESPRIT I
- Trial Scorecard: INTERHEART
- Trial Scorecard: ROPAC
- Trial Scorecard: TACTICS-HF
- Trial Scorecard: TARIFF
- Hypertensive disorders during pregnancy: A window into future CV risk Ki Park, MD, MS, FSCAI